sglt2 inhibitors and glp-1 receptor agonists Diabetic Agents, From Metformin to GLP1 Agonists: JACC Focus Seminar Metabolic Powerhouses: GLP-1 RAs and

Alcohol and its metabolites act as pro-carcinogens via chronic inflammation and gene instability [14]

Youll be able to find clinical trials at all different phases, including: New, not yet recruiting Active, recruiting Active, not recruiting Completed One thing to keep in mind: Clinicaltrials.gov is maintained by The National Library of Medicine (NLM), but the government doesnt review or approve the safety of the clinical trials

The authors also stressed that the use of these medications should be viewed in a broader health context, including issues such as access, affordability, and insurance coverage, so that existing health inequities are not made worse

Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: a meta-analysis

Specific to cardiovascular-related death, ELIXA and SUSTAIN-6 trials showed similar performance relative to the placebo [ HR = 0.98 (95% CI 0.781.22) and HR = 0.98 (95% CI 0.651.48), respectively]

Zepbound and Orforglipron, if approved, will be an average of $346/month